-
-
Humanized model of the immune system
-
iHuPBMC-T
-
iHuPBMC-NK
-
iHuPBMC-B
-
PBMC-LT
-
CD34+ HSC
-
Winn model
-
iHuPBMC-MHC/KO
-
iHuPBMC-OncVax
-
PBMC mixed inoculation model
more -
-
In vivo tumor experimental platform
-
CDX
-
iHuPDX
-
Non-GLP Toxicology
-
PK/PD
-
Brain in situ model
-
Other in situ models
-
Hematologic tumor model system inoculation
-
Creation of high interstitial tumor models
more -
-
In vitro killing experiment platform
-
Immune co-culture killing model
-
CDC
-
In vitro killing experiment platform
-
IC50
-
PDC High-Throughput In Vitro Pharmacodynamics
-
3D organoids
-
ADCC
-
T cell-mediated killing experiment
more -
-
Mouse-derived immune system model
more -
Tumor vaccine
more -
Cell therapy
more -
In vitro testing platform
more -
Non-GLP Toxicology Platform
more -
Non-tumor model and drug efficacy evaluation platform
more
-
-
-
PDX model
-
PDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
CDX model
-
CDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
Homogeneous Model
-
Homogeneous Model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Breast cancer
-
Stomach cancer
-
Liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Pancreatic cancer
-
Kidney cancer
-
Bladder cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer
-
Ovarian cancer
-
Esophageal cancer
-
Skin cancer
-
sarcoma
-
Nervous System Cancer
-
Embryonal carcinoma
-
Lymphoma
-
Leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other
-
Colorectal cancer
more -
-
News Center
——
InnoModels Biotechnology ELISpot platform: a powerful tool to precisely analyze the immune response
Author:
InnoModels
Release time:
2024-10-18
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Biotechnology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality.
1. Platform Introduction
InnoModels' ELISpot platform is a cellular detection technology that combines high sensitivity and high precision. By detecting cytokines secreted by individual cells, it is able to analyze in detail the response and function of immune cells such as T cells and B cells, and has demonstrated excellent performance in the study of cytotoxic T lymphocytes (CTLs) and their immune response.
2. Core Advantages
Multiple CTL stimulation methods: The platform provides multiple CTL stimulation methods, including in vitro specific antigen presentation using human or mouse peripheral blood mononuclear cells (PBMCs) or spleen immune cells. It is also possible to analyze peripheral blood or spleen cells after immunization in immunologically sound mice to ensure comprehensive and accurate results.
Specific MHC antigen presentation: The platform utilizes a specific MHC antigen presentation pathway to activate CTLs, ensuring that CTL activation is strictly dependent on the presence of the appropriate MHC molecule, thus avoiding non-specific activation in the event of an MHC mismatch and improving the reliability of experimental results.
Highly Sensitive Detection: The ELISpot platform is known for its high sensitivity, capable of detecting even low levels of CTL responses. This enables researchers to accurately measure and analyze CTL activity in different biological samples, providing a powerful tool for in-depth study of immune responses.
Quantitative and Qualitative Analysis: The platform provides the ability to quantitatively and qualitatively analyze CTL production levels, allowing researchers to comprehensively assess the quantity and quality of CTL responses. This analytical capability is critical for understanding and monitoring the immune response process, and plays a particularly important role in cancer vaccine research and tumor immunotherapy development.
3. Application Areas
InnoModels' ELISpot platform is widely used in tumor vaccine research, immunomodulatory drug development, and individualized medicine. Through the platform, researchers can deeply explore the mechanism of CTL in anti-tumor immunity, evaluate the effectiveness of tumor vaccines, and screen potential immunomodulatory drugs. In addition, the platform is also applicable to the analysis of clinical patient samples, providing a scientific basis for the development of individualized medical treatment plans.
4、Summary and Prospect
The emergence of the InnoModels Biotechnology ELISpot platform has revolutionized the field of immunology research. Its high sensitivity, multifunctionality and wide range of application prospects have made the platform an indispensable research tool for researchers. With the continuous development and improvement of the technology, it is believed that the ELISpot platform will play an even more important role in future scientific research and clinical applications, and contribute more to the cause of human health.
Next Page
Chuangmo Biotechnology (Beijing) Co., Ltd.
-
Telephone:+8615010000264 +8613810723384
-
E-mail:cndw@imodels.tech
-
Address: Building 14, Life Valley, Shuangying West Road, Changping District, Beijing
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
Chuangmo Biotechnology (Beijing) Co., Ltd